- authorisedTherapeutic exploratory (Phase II)
Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)
This study is looking at a new combination of two drugs, axitinib and avelumab, for people with a common type of kidney cancer before surgery. The main goal is to see how well this drug combination shrinks the cancer.
Netherlands - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium - active not recruitingPHASE2
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
This study is looking at different combinations of immunotherapy medicines given before surgery for kidney cancer. It aims to see if these treatments can shrink tumours and improve outcomes for people with clear cell renal cell carcinoma.
Netherlands · United Kingdom - authorisedTherapeutic use (Phase IV)
Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma
This study looks at how closely watching how much Cabozantinib medicine is in your body can help manage side effects for kidney cancer patients. The goal is to reduce treatment interruptions by improving how we deal with these side effects.
Italy - active not recruitingPHASE2
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
This study uses a special scan called a PET/CT with a medicine called zirconium Zr 89 crefmirlimab berdoxam. It’s for people with advanced melanoma, Merkel cell cancer, kidney cancer, or lung cancer. We want to see if this scan can help predict how well immunotherapy will work for their cancer.
United States · Australia · Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors
This study is looking into a new medicine called QEQ278 for people with advanced cancers like lung, oesophageal, kidney, or head and neck cancer. It's the very first time this medicine is being given to people, and the main aim is to see if it's safe to use and how well people tolerate it.
France · Italy · Germany - active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
United States · Australia · Belgium - active not recruitingPHASE3
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is testing new combinations of medicines (Nivolumab with Cabozantinib) against a standard treatment (Sunitinib) for kidney cancer that has spread. We want to see if the new combination is safer and works better for people who haven't had treatment before.
United States · Argentina · Australia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
This study looks at a medicine called Keytruda after surgery for kidney cancer to see if it stops the cancer from coming back. It compares Keytruda to a dummy medicine to find out if it's safe and effective.
Netherlands · Poland · Finland - recruitingPHASE1, PHASE2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
This study looks at new drug combinations for kidney cancer (renal cell carcinoma) that has come back after previous treatment. It aims to find out if these combinations are safe and effective. It's for people aged 18-120 with this specific type of kidney cancer.
United States · Chile · France - active not recruitingPHASE3
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It combines three medicines to see if they work better together than two, aiming to help people live longer and keep their cancer from growing.
United States · Argentina · Australia - ongoing, recruitingTherapeutic confirmatory (Phase III)
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
This study is for people with kidney cancer that has grown or come back after previous treatments. It compares a new combination of two drugs, tivozanib and nivolumab, against tivozanib on its own. The aim is to see if the combination helps people live longer without their cancer growing.
Italy · Germany · Poland - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - active not recruitingPHASE2
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
This study looks at new drug combinations for kidney cancer that has spread or can't be removed. It compares different immune-boosting medicines with a drug called axitinib to see how safe and effective they are.
United States · Australia · China - recruitingNA
Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management
This study looks at a new way to give radiotherapy for kidney cancer, both when it's just in one place or has spread. It compares the usual treatment to a shorter, more intense course to see if it's safe and practical.
United Kingdom - active not recruitingPHASE2
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
This study is testing a new combination of treatments, Intismeran autogene and Pembrolizumab, for kidney cancer. We want to see if this combination, given after surgery, can help stop the cancer from coming back for longer compared to Pembrolizumab alone.
United States · Argentina · Australia - recruitingPHASE1
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This study is testing a new medicine for people with advanced cancers that haven't responded to other treatments. It aims to see how safe the medicine is, how it moves through the body, and what dose works best.
United States · Canada - recruitingPHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
This study is looking for better ways to treat advanced kidney cancer that has come back after earlier treatment. Researchers want to see if a new combination of medicines, belzutifan and zanzalintinib, works better than a standard medicine, cabozantinib, at shrinking the cancer.
Argentina · Australia · Austria - recruitingPHASE3
Renal Adjuvant MultiPle Arm Randomised Trial
This study looks at new treatments for kidney cancer (renal cell carcinoma) after surgery. It compares two drugs, durvalumab and tremelimumab, given alone or together, against standard monitoring. The aim is to see if these drugs can stop the cancer from coming back or help people live longer.
United Kingdom - active not recruitingPHASE3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.
United States · Australia · Austria - recruitingPHASE1
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
This study in Canada tests a new treatment, GCAR1, for specific advanced cancers like certain breast, kidney, and bone cancers. Researchers want to find the safest dose and see if it helps slow down cancer by using the body's own immune cells.
Canada - recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
This study looks at a new blood test to find cancer early in people who have already been treated for certain cancers. It aims to see if this test can tell when cancer might come back, helping doctors give the best care sooner.
United States · France · Germany - not yet recruitingPHASE2
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
This study looks at a new way to check how aggressive kidney cancer (renal cell carcinoma) is before surgery. We're using a special scan called a PET scan with a substance called 82-Rb. This helps doctors see if the scan can tell the difference between less aggressive and more aggressive cancers.
France - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This study is testing a drug called alectinib for different types of cancer that have a special gene change called ALK. It's already used for some lung cancers, and now doctors want to see if it can help other cancers with the same change.
United Kingdom - recruiting
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
This study looks at combining special cancer drugs (PD-1/PD-L1 inhibitors) with radiation. It aims to see how well this works for various cancers and if we can find new ways to predict who will benefit most from this treatment.
Germany - recruitingNA
Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
This study looks at a special type of radiation, called SBRT, for kidney cancer when surgery isn't an option. It checks if SBRT works, how it affects quality of life, and if it's safe. It's for patients who can't have or don't want surgery for their kidney cancer.
Canada